CPT1A and glioblastoma: These observations prompted us to test the hypothesis that alisertib along with the clinical validated FAO inhibitor, etomoxir, which binds and blocks the mitochondrial fatty acid transporter CPT1A, would reduce the cellular viability of GBM cells in a more than additive manner.